Cardiac Organoid Co-Culture System for CHIP Mutation Modeling
Solution Overview
Problem
Current technologies lack an effective model for simulating the interaction between myeloid/lymphoid/hematopoietic stem cells and cardiac tissue to study the impact of CHIP-related mutations on heart health, which is crucial for drug screening and understanding cardiovascular diseases.
Innovation Solution
A cardiac cell culture model system is developed, comprising cardiac organoids and myeloid, lymphoid, or hematopoietic cells, allowing for co-culture and genetic modification to assess the biological interactions, infiltration, and phenotypic effects, enabling the evaluation of pharmaceutical compounds' impact on these interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a dual-component co-culture system is established to model CHIP interactions, then the biological realism and disease modeling capability are improved, but the device complexity and operational difficulty increase
Solution Approach 1:
The system is segmented into distinct modular components: cardiac organoids in lower wells and hematopoietic cells in upper wells of a Transwell insert system. This segmentation allows independent preparation and maintenance of each cell type while enabling controlled interaction through defined interfaces (membrane pores), thereby improving reliability without overwhelming complexity
Solution Approach 2:
The Transwell insert membrane acts as an intermediary structure that facilitates controlled interaction between cardiac organoids and hematopoietic cells. The membrane allows selective passage of cells and molecules while maintaining physical separation, enabling realistic CHIP interaction modeling through a manageable intermediate component
2Measurement precision
If genetic modifications are introduced to hematopoietic cells to model CHIP mutations, then the specificity and accuracy of disease modeling are improved, but the manufacturing complexity and time requirements increase
Solution Approach 1:
Genetic modifications (CRISPR/Cas9, transduction) are performed on hematopoietic cells in advance before co-culture establishment. Cells are genetically engineered, validated, and expanded separately, allowing sufficient time for complex genetic manipulation without delaying the overall experiment. Pre-modified cells are then ready for immediate co-culture with cardiac organoids
Solution Approach 2:
Standardized genetic modification protocols and validated cell lines are used to create consistent CHIP models. Once a genetic modification protocol is established for a particular mutation, it can be replicated across multiple experiments and laboratories, reducing manufacturing complexity through proven copyable methods
3Duration of action of moving object
If long-term co-culture maintenance is implemented to study chronic CHIP effects, then the duration and depth of biological interaction assessment are improved, but the operational burden and resource consumption increase
Solution Approach 1:
The Transwell co-culture system is designed to maintain continuous biological interaction between hematopoietic cells and cardiac organoids over extended periods (weeks to months). The modular design allows for sustained co-culture with periodic media changes and monitoring, enabling chronic CHIP effect studies without requiring constant intervention or re-establishment of interactions
Solution Approach 2:
The co-culture system is designed to maintain itself with minimal intervention. Once established, the system sustains cell viability and interactions through its own microenvironment, requiring only periodic media changes. The structural design (Transwell inserts, organoid containment) maintains physical organization automatically, reducing operational burden during long-term culture
Data Source
AI summary
The present invention relates to a cardiac cell culture model system composed of a cardiac organoid and blood or blood precursor cells. The cardiac cell culture model system serves as a model for the heart, and the present invention also relates to drug screening with the cardiac cell culture model system investigating the impact of the drug on the heart.



